Epigenome-Extensive Affiliation Research Reveals Methylation Loci Related With Offspring Gestational Diabetes Mellitus Publicity and Maternal Methylome
Goal: Gestational diabetes mellitus (GDM) is related to an elevated danger of weight problems and insulin resistance in offspring later in life, which could be defined by epigenetic modifications in response to maternal hyperglycemic publicity.
Analysis design and strategies: We explored the affiliation between GDM publicity and maternal blood and new child wire blood methylation in 536 mother-offspring pairs from the possible FinnGeDi cohort utilizing Illumina MethylationEPIC 850Ok BeadChip arrays. We assessed two hypotheses. First, we examined for shared maternal and offspring epigenetic results ensuing from GDM publicity. Second, we examined whether or not GDM publicity and maternal methylation had an epigenetic impact on the offspring.
Outcomes: We didn’t discover any epigenetic marks (differentially methylated CpG probes) with shared and constant results between moms and offspring. After together with maternal methylation within the mannequin, we recognized a single vital (false discovery price 1.38 × 10-2) CpG on the cg22790973 probe (TFCP2) related to GDM. We recognized seven extra FDR-significant interactions of maternal methylation and GDM standing, with the strongest affiliation on the identical cg22790973 probe (TFCP2), in addition to cg03456133, cg24440941 (H3C6), cg20002843 (LOC127841), cg19107264, and cg11493553 situated throughout the UBE3C gene and cg17065901 in FAM13A, each susceptibility genes for sort 2 diabetes and BMI, and cg23355087 throughout the DLGAP2 gene, identified to be concerned in insulin resistance throughout being pregnant.
Conclusions: Our examine reveals the potential complexity of the epigenetic transmission between moms with GDM and their offspring, seemingly decided by not solely GDM publicity but additionally different elements indicated by maternal epigenetic standing, similar to maternal metabolic historical past.

RRAD Antibody |
|||
R34275-100UG | NSJ Bioreagents | 100 ug | EUR 399 |
RRAD Antibody |
|||
CSB-PA233809- | Cusabio | each | EUR 402 |
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500 |
Rrad/ Rat Rrad ELISA Kit |
|||
ELI-14921r | Lifescience Market | 96 Tests | EUR 1063.2 |
RRAD Conjugated Antibody |
|||
C37229 | SAB | 100ul | EUR 476.4 |
Polyclonal RRAD Antibody |
|||
APR05556G | Leading Biology | 0.1ml | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human RRAD . This antibody is tested and proven to work in the following applications: |
RRAD siRNA |
|||
20-abx932133 | Abbexa |
|
|
RRAD Peptide |
|||
43-008P | ProSci | 0.1 mg | EUR 405.6 |
Description: RRAD Peptide |
RRAD Blocking Peptide |
|||
33R-4793 | Fitzgerald | 100 ug | EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5797 |
RRAD Blocking Peptide |
|||
33R-10070 | Fitzgerald | 100 ug | EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5798 |
RRAD Blocking Peptide |
|||
20-abx063234 | Abbexa |
|
|
Anti-RRAD (aa36-48) antibody |
|||
STJ72757 | St John's Laboratory | 100 µg | EUR 430.8 |
Human RRAD shRNA Plasmid |
|||
20-abx954199 | Abbexa |
|
|
RRAD ELISA KIT|Human |
|||
EF005507 | Lifescience Market | 96 Tests | EUR 826.8 |
RRAD Recombinant Protein (Human) |
|||
RP095493 | ABM | 100 ug | Ask for price |
RRAD Recombinant Protein (Rat) |
|||
RP226925 | ABM | 100 ug | Ask for price |
RRAD Recombinant Protein (Mouse) |
|||
RP169340 | ABM | 100 ug | Ask for price |
GTP-Binding Protein RAD (RRAD) Antibody |
|||
20-abx008742 | Abbexa |
|
|
GTP-binding protein RAD (RRAD) Antibody |
|||
abx332370-100ul | Abbexa | 100 ul | EUR 510 |
GTP-Binding Protein RAD (RRAD) Antibody |
|||
abx432011-200ul | Abbexa | 200 ul | EUR 460.8 |
GTP-binding protein RAD (RRAD) Antibody |
|||
20-abx324872 | Abbexa |
|
|
GTP-binding protein RAD (RRAD) Antibody |
|||
20-abx241706 | Abbexa |
|
|
GTP-binding protein RAD (RRAD) Antibody |
|||
20-abx214509 | Abbexa |
|
|
Rrad ORF Vector (Rat) (pORF) |
|||
ORF075643 | ABM | 1.0 ug DNA | EUR 607.2 |
Rrad ORF Vector (Mouse) (pORF) |
|||
ORF056448 | ABM | 1.0 ug DNA | EUR 607.2 |
RRAD ORF Vector (Human) (pORF) |
|||
ORF031832 | ABM | 1.0 ug DNA | EUR 486 |
Polyclonal RRAD (aa36-48) Antibody (internal region) |
|||
APG00807G | Leading Biology | 0.1mg | EUR 580.8 |
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human RRAD (aa36-48) (internal region). This antibody is tested and proven to work in the following applications: |
RRAD And GEM Like GTPase 2 (REM2) Antibody |
|||
abx122938-100ug | Abbexa | 100 ug | EUR 469.2 |
RRAD And GEM Like GTPase 2 (REM2) Antibody |
|||
abx237237-100ug | Abbexa | 100 ug | EUR 661.2 |
Rrad sgRNA CRISPR Lentivector set (Rat) |
|||
K7052701 | ABM | 3 x 1.0 ug | EUR 406.8 |
Rrad sgRNA CRISPR Lentivector set (Mouse) |
|||
K3480701 | ABM | 3 x 1.0 ug | EUR 406.8 |
RRAD sgRNA CRISPR Lentivector set (Human) |
|||
K2069901 | ABM | 3 x 1.0 ug | EUR 406.8 |
Rrad sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
K7052702 | ABM | 1.0 ug DNA | EUR 184.8 |
Rrad sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
K7052703 | ABM | 1.0 ug DNA | EUR 184.8 |
Rrad sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
K7052704 | ABM | 1.0 ug DNA | EUR 184.8 |
Rrad sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
K3480702 | ABM | 1.0 ug DNA | EUR 184.8 |
Rrad sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
K3480703 | ABM | 1.0 ug DNA | EUR 184.8 |
Rrad sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
K3480704 | ABM | 1.0 ug DNA | EUR 184.8 |
RRAD sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
K2069902 | ABM | 1.0 ug DNA | EUR 184.8 |
RRAD sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
K2069903 | ABM | 1.0 ug DNA | EUR 184.8 |
RRAD sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
K2069904 | ABM | 1.0 ug DNA | EUR 184.8 |
RRAD Protein Vector (Human) (pPB-C-His) |
|||
PV127326 | ABM | 500 ng | EUR 662.4 |
RRAD Protein Vector (Human) (pPB-N-His) |
|||
PV127327 | ABM | 500 ng | EUR 662.4 |
RRAD Protein Vector (Human) (pPM-C-HA) |
|||
PV127328 | ABM | 500 ng | EUR 662.4 |
RRAD Protein Vector (Human) (pPM-C-His) |
|||
PV127329 | ABM | 500 ng | EUR 662.4 |
RRAD Protein Vector (Rat) (pPB-C-His) |
|||
PV302570 | ABM | 500 ng | EUR 723.6 |
RRAD Protein Vector (Rat) (pPB-N-His) |
|||
PV302571 | ABM | 500 ng | EUR 723.6 |
RRAD Protein Vector (Rat) (pPM-C-HA) |
|||
PV302572 | ABM | 500 ng | EUR 723.6 |
RRAD Protein Vector (Rat) (pPM-C-His) |
|||
PV302573 | ABM | 500 ng | EUR 723.6 |
RRAD Protein Vector (Mouse) (pPB-C-His) |
|||
PV225790 | ABM | 500 ng | EUR 723.6 |
RRAD Protein Vector (Mouse) (pPB-N-His) |
|||
PV225791 | ABM | 500 ng | EUR 723.6 |
RRAD Protein Vector (Mouse) (pPM-C-HA) |
|||
PV225792 | ABM | 500 ng | EUR 723.6 |
RRAD Protein Vector (Mouse) (pPM-C-His) |
|||
PV225793 | ABM | 500 ng | EUR 723.6 |
Rrad 3'UTR Luciferase Stable Cell Line |
|||
TU219725 | ABM | 1.0 ml | Ask for price |
Rrad 3'UTR GFP Stable Cell Line |
|||
TU168183 | ABM | 1.0 ml | Ask for price |
Rrad 3'UTR GFP Stable Cell Line |
|||
TU269725 | ABM | 1.0 ml | Ask for price |
Rrad 3'UTR Luciferase Stable Cell Line |
|||
TU118183 | ABM | 1.0 ml | Ask for price |
RRAD 3'UTR GFP Stable Cell Line |
|||
TU072380 | ABM | 1.0 ml | EUR 1672.8 |
RRAD 3'UTR Luciferase Stable Cell Line |
|||
TU022380 | ABM | 1.0 ml | EUR 1672.8 |
Human GTP-binding protein RAD (RRAD) ELISA Kit |
|||
abx385354-96tests | Abbexa | 96 tests | EUR 1093.2 |
Rat GTP-binding protein RAD (RRAD) ELISA Kit |
|||
abx391893-96tests | Abbexa | 96 tests | EUR 1093.2 |
Mouse GTP-binding protein RAD (RRAD) ELISA Kit |
|||
abx390415-96tests | Abbexa | 96 tests | EUR 1093.2 |
RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
LV658369 | ABM | 1.0 ug DNA | EUR 616.8 |
RRAD Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
LV658373 | ABM | 1.0 ug DNA | EUR 616.8 |
RRAD Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
LV658374 | ABM | 1.0 ug DNA | EUR 616.8 |
Human GTP- binding protein RAD, RRAD ELISA KIT |
|||
ELI-35549h | Lifescience Market | 96 Tests | EUR 988.8 |
Mouse GTP- binding protein RAD, Rrad ELISA KIT |
|||
ELI-14089m | Lifescience Market | 96 Tests | EUR 1038 |
Human RRAD And GEM Like GTPase 2 (REM2) ELISA Kit |
|||
abx382769-96tests | Abbexa | 96 tests | EUR 1093.2 |
Rrad ELISA Kit| Mouse GTP-binding protein RAD ELISA Kit |
|||
EF016057 | Lifescience Market | 96 Tests | EUR 826.8 |
Rrad ELISA Kit| Rat GTP-binding protein RAD ELISA Kit |
|||
EF019253 | Lifescience Market | 96 Tests | EUR 826.8 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
K7052705 | ABM | 3 x 1.0 ug | EUR 451.2 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
K3480705 | ABM | 3 x 1.0 ug | EUR 451.2 |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
K2069905 | ABM | 3 x 1.0 ug | EUR 451.2 |
RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
LV658370 | ABM | 1.0 ug DNA | EUR 616.8 |
RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
LV658371 | ABM | 1.0 ug DNA | EUR 686.4 |
RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
LV658372 | ABM | 1.0 ug DNA | EUR 686.4 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
K7052706 | ABM | 1.0 ug DNA | EUR 200.4 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
K7052707 | ABM | 1.0 ug DNA | EUR 200.4 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
K7052708 | ABM | 1.0 ug DNA | EUR 200.4 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|||
K3480706 | ABM | 1.0 ug DNA | EUR 200.4 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|||
K3480707 | ABM | 1.0 ug DNA | EUR 200.4 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|||
K3480708 | ABM | 1.0 ug DNA | EUR 200.4 |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
K2069906 | ABM | 1.0 ug DNA | EUR 200.4 |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
K2069907 | ABM | 1.0 ug DNA | EUR 200.4 |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
K2069908 | ABM | 1.0 ug DNA | EUR 200.4 |
Positive control tissue section for each individua |
|||
Control-Slides-for-each-antibody | Innovex | Set of 25 | EUR 355 |
Description: Positive control tissue section for each individual antibody; Based on availability; INQUIRE |
ASAP1 antibody Antibody |
|||
DF8746 | Affbiotech | 200ul | EUR 420 |
CD11b Antibody Antibody |
|||
ABD2911 | Lifescience Market | 100 ug | EUR 525.6 |
anti- Antibody^Polyclonal antibody control antibody |
|||
LSMab09882 | Lifescience Market | 100 ug | EUR 525.6 |
ARHGDIA Antibody / RHOGDI Antibody |
|||
F54788-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 165 |
ARHGDIA Antibody / RHOGDI Antibody |
|||
F54788-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 379 |
Antibody |
|||
A1360-500 | Biovision | each | Ask for price |
Ly1 Antibody Reactive (LYAR) Antibody |
|||
20-abx123734 | Abbexa |
|
|
Anti-Glycolipid Antibody (AGA) Antibody |
|||
20-abx004855 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
20-abx014333 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
20-abx008109 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
abx033330-400ul | Abbexa | 400 ul | EUR 627.6 |
Ly1 Antibody Reactive (LYAR) Antibody |
|||
abx033330-80l | Abbexa | 80 µl | EUR 343.2 |
Anti-Glycolipid Antibody (AGA) Antibody |
|||
abx036399-100ug | Abbexa | 100 ug | EUR 469.2 |
Anti-Glycolipid Antibody (AGA) Antibody |
|||
abx230204-100ug | Abbexa | 100 ug | EUR 577.2 |
Anti-Glycoprotein Antibody (GP) Antibody |
|||
20-abx319900 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
20-abx319901 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
20-abx319905 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
20-abx319913 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
20-abx311665 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
20-abx324434 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
abx234901-100ug | Abbexa | 100 ug | EUR 661.2 |
Anti-Anti-SEPT6 antibody antibody |
|||
STJ11100949 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined. |
Anti-Anti-SEPT9 Antibody antibody |
|||
STJ111369 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described. |
Anti-Anti-SEPT11 Antibody antibody |
|||
STJ111530 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT4 Antibody antibody |
|||
STJ112276 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer. |
Anti-Anti-MARCH9 Antibody antibody |
|||
STJ112609 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT2 Antibody antibody |
|||
STJ25475 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT5 Antibody antibody |
|||
STJ25477 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
Anti-Anti-SEPT8 Antibody antibody |
|||
STJ25479 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-SEPT2 Antibody antibody |
|||
STJ28365 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT7 Antibody antibody |
|||
STJ28963 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
Anti-Anti-SEPT1 antibody antibody |
|||
STJ119580 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012] |
Anti-Anti-SEPT12 Antibody antibody |
|||
STJ117759 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-MARCH6 Antibody antibody |
|||
STJ118549 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-MARCH6 Antibody antibody |
|||
STJ118550 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-MARCH7 Antibody antibody |
|||
STJ118752 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT3 Antibody antibody |
|||
STJ118990 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT11 Antibody antibody |
|||
STJ113941 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT11 Antibody antibody |
|||
STJ114081 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT5 Antibody antibody |
|||
STJ114819 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
Anti-Anti-MARCH8 Antibody antibody |
|||
STJ114828 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT7 Antibody antibody |
|||
STJ116214 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
Anti-Anti-SEPT8 Antibody antibody |
|||
STJ117206 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
CLCN5 Antibody / CIC-5 antibody |
|||
RQ6462 | NSJ Bioreagents | 100ug | EUR 419 |
Description: The CLCN5 gene encodes the chloride channel Cl-/H+ exchanger ClC-5. This gene encodes a member of the ClC family of chloride ion channels and ion transporters. The encoded protein is primarily localized to endosomal membranes and may function to facilitate albumin uptake by the renal proximal tubule. Mutations in this gene have been found in Dent disease and renal tubular disorders complicated by nephrolithiasis. Alternatively spliced transcript variants have been found for this gene. |
Cytokeratin 7 antibody-Cytoskeleton Marker Antibody |
|||
48169-100ul | SAB | 100ul | EUR 399.6 |
Cytokeratin 7 antibody-Cytoskeleton Marker Antibody |
|||
48169-50ul | SAB | 50ul | EUR 286.8 |
Antibody Pair to ApoA-V antibody |
|||
10R-1876 | Fitzgerald | 100 ul | EUR 781.2 |
Description: Mouse monoclonal Antibody Pair to ApoA-V antibody |
Anti CD22 Antibody: CD22 Monoclonal Antibody |
|||
065-A-01mg | Virogen | 0,1 mg | EUR 321 |
Description: anti-CD22 monoclonal antibody |
Anti CD22 Antibody: CD22 Monoclonal Antibody |
|||
065-A-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: anti-CD22 monoclonal antibody |
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
20-abx103034 | Abbexa |
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
20-abx103035 | Abbexa |
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
20-abx103036 | Abbexa |
|
|
Hepatitis C Virus Antibody (HCV) Antibody |
|||
abx023924-1mg | Abbexa | 1 mg | EUR 1446 |
Anti-Glycoprotein 210 Antibody (gp210) Antibody |
|||
abx233571-100ug | Abbexa | 100 ug | EUR 577.2 |
Anti Deoxyribonucleic Acid Antibody (DNA) Antibody |
|||
abx411057-50ug | Abbexa | 50 ug | EUR 710.4 |
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
20-abx319902 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
20-abx319903 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
20-abx319904 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
20-abx319906 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
20-abx319907 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
20-abx319908 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
20-abx319914 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
20-abx319915 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
20-abx319916 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
20-abx319929 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
20-abx319930 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
20-abx319931 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (HRP) |
|||
20-abx311666 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (FITC) |
|||
20-abx311667 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (Biotin) |
|||
20-abx311668 | Abbexa |
|
|
Monoclonal NGF/proNGF Neutralizing Antibody Antibody |
|||
AMM06679G | Leading Biology | 0.05mg | EUR 633.6 |
Description: A Monoclonal antibody against Human NGF/proNGF Neutralizing. The antibodies are raised in Mouse. This antibody is applicable in E |
Goat anti- human Antibody^Polyclonal antibody |
|||
LSMab09896 | Lifescience Market | 100 ug | EUR 525.6 |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D | Stressmarq | 0.1mg | EUR 424.8 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-A390 | Stressmarq | 0.1mg | EUR 481.2 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 390. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-A488 | Stressmarq | 0.1mg | EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 488. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-A565 | Stressmarq | 0.1mg | EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 565. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-A594 | Stressmarq | 0.1mg | EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 594. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-A633 | Stressmarq | 0.1mg | EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 633. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-A655 | Stressmarq | 0.1mg | EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 655. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-A680 | Stressmarq | 0.1mg | EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 680. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-A700 | Stressmarq | 0.1mg | EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 700. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-ALP | Stressmarq | 0.1mg | EUR 472.8 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Alkaline Phosphatase. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-APC | Stressmarq | 0.1mg | EUR 478.8 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC . |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-APCCY7 | Stressmarq | 0.1mg | EUR 565.2 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC/Cy7. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-BI | Stressmarq | 0.1mg | EUR 475.2 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Biotin. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-DY350 | Stressmarq | 0.1mg | EUR 496.8 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 350. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-DY405 | Stressmarq | 0.1mg | EUR 483.6 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 405. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-DY488 | Stressmarq | 0.1mg | EUR 471.6 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 488. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-DY594 | Stressmarq | 0.1mg | EUR 474 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 594. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-DY633 | Stressmarq | 0.1mg | EUR 468 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 633. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-FITC | Stressmarq | 0.1mg | EUR 470.4 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to FITC. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-HRP | Stressmarq | 0.1mg | EUR 465.6 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to HRP. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-P594 | Stressmarq | 0.1mg | EUR 488.4 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to PE/ATTO 594. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-PCP | Stressmarq | 0.1mg | EUR 478.8 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to PerCP. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-RPE | Stressmarq | 0.1mg | EUR 476.4 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to RPE . |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-STR | Stressmarq | 0.1mg | EUR 477.6 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Streptavidin. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692S | Stressmarq | 0.012mg | EUR 78 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated. |
Anti-IgG1 Negative Control Antibody antibody |
|||
STJ16100881 | St John's Laboratory | 1 mL | EUR 573.6 |
Anti-Noelin Antibody BIOTIN Antibody BIOTIN |
|||
STJ501938 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-Noelin Antibody FITC Antibody FITC |
|||
STJ501939 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-Noelin Antibody BIOTIN Antibody BIOTIN |
|||
STJ501940 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-Noelin Antibody FITC Antibody FITC |
|||
STJ501941 | St John's Laboratory | 100 µg | EUR 703.2 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
R20161-100UG | NSJ Bioreagents | 100ug | EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
R20161BTN-50UG | NSJ Bioreagents | 50ug | EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
R20161SAF-250UG | NSJ Bioreagents | 250ug | EUR 979 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
R20179-100UG | NSJ Bioreagents | 100ug | EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
R20179BTN-50UG | NSJ Bioreagents | 50ug | EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
R20179SAF-250UG | NSJ Bioreagents | 250ug | EUR 979 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
RQ4975 | NSJ Bioreagents | 100ul | EUR 419 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
V7875-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
|||
V7875-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
|||
V7875SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
|||
V7878-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Metformin use is related to a decreased danger of acute appendicitis in Taiwanese sufferers with sort 2 diabetes mellitus
This retrospective cohort examine used the nationwide database of Taiwan’s Nationwide Well being Insurance coverage to analyze whether or not metformin would cut back the chance of acute appendicitis in sufferers with sort 2 diabetes mellitus. We first recognized 423,949 sufferers newly recognized of diabetes from 1999 to 2005. After excluding sufferers having sort 1 diabetes mellitus, lacking knowledge, earlier historical past of acute appendicitis, aged < 15 years, aged > 80 years and adopted up for < 6 months, 338,172 ever customers and 21,861 by no means customers of metformin had been adopted up from January 1, 2006 till December 31, 2011.
Incidence of acute appendicitis was estimated for by no means customers, ever customers and subgroups (divided by median, tertiles and quartiles, respectively) of dose-response indicators together with cumulative period (months), cumulative dose (mg) and common day by day dose (mg/day) of metformin remedy. We used Cox regression included with the inverse chance of remedy weighting utilizing propensity rating to estimate the general hazard ratio for ever versus by no means customers, and the hazard ratios for subgroups of dose-response indicators versus by no means customers.
Outcomes confirmed that new-onset acute appendicitis was recognized in 1558 ever customers and 179 by no means customers throughout follow-up. The incidence was 98.15 per 100,000 person-years in ever customers and was 189.48 per 100,000 person-years in by no means customers. The general hazard ratio (95% confidence interval) of 0.514 (0.441-0.600) instructed a decrease danger of acute appendicitis related to metformin use. A dose-response sample was constantly noticed within the analyses of various subgroups of dose-response indicators and the decreased danger related to metformin use was constantly noticed in numerous sensitivity analyses.
A median day by day dose of 1000-1500 mg/day can considerably scale back the chance by > 50%. The profit didn’t differ between totally different formulations of metformin, and the estimated hazard ratio for standard/immediate-release metformin versus by no means customers was 0.516 (0.441-0.603) and was 0.509 (0.421-0.615) for extended/slow-release metformin versus by no means customers. It’s concluded that metformin use is related to a decreased danger of acute appendicitis in sufferers with sort 2 diabetes mellitus.
Affiliation of severity of diabetic retinopathy with corneal endothelial and thickness modifications in sufferers with diabetes mellitus
Goal: To analyse the central corneal thickness, endothelial cell density and morphology in sufferers with diabetes mellitus (DM).
Strategies: We analysed corneal endothelium, i.e. central corneal thickness (CCT), endothelial cell density (ECD), coefficient of variation in cell measurement (CV), and hexagonality (Hex) with specular microscopy in sufferers with sort 2 DM and in contrast with age-matched controls. The affect of diabetic retinopathy (DR) severity, period of DM, and degree of glycosylated haemoglobin (HbA1c) was additionally analysed.
Outcomes: The examine cohort included 592 eyes of 592 diabetic sufferers and 596 eyes of 596 management topics. A big distinction was present in CCT (522.1 ± 36.6 μm in DM, 514.9 ± 37.1 μm in controls; P = 0.001), ECD (2484.5 ± 299.5 cells/mm2 in DM, 2555.9 ± 258.2 cells/mm2 in controls; P = 0.017), CV (40.3 ± 6.1 in DM, 37.2 ± 6.1 in controls; P < 0.001) and Hex (39.9 ± 5.2 in DM, 44.6 ± 6.Zero in controls; P < 0.001). The longer period of DM ( > 10 years) and poor glycaemic management (HbA1c > 7.5%) had been related to related outcomes. A considerably decreased ECD (P < 0.001) and Hex (P = 0.001) and better CV (P = 0.007) and CCT (P = 0.01) was famous when assessed towards numerous phases of DR. Multivariate evaluation confirmed that growing age was considerably related to decrease ECD (P < 0.001), Hex (P < 0.001), and CCT (P = 0.004); and the next CV (P < 0.001).
Conclusions: DM has deleterious results on corneal endothelium and thickness. The presence of DR might additional warrant a radical corneal analysis, particularly when planning intraocular surgical procedure.
Affiliation of interior retinal reflectivity with qualitative and quantitative modifications in retinal layers over time in diabetic eyes with out retinopathy
Goal: To evaluate the course of neurodegeneration primarily based on retinal layer thickness and integrity evaluation in diabetic sufferers with out retinopathy and to judge its affiliation with interior retinal reflectivity.
Strategies: This retrospective case-control examine included 80 eyes of 80 sufferers with DM with out retinopathy and 40 eyes of 40 wholesome topics with a follow-up of ≥1 12 months. SD-OCT was used for evaluation of retinal reflectivity and macular layer thicknesses. Optical depth ratios (OIRs) had been outlined because the imply OCT reflectivity of ganglion cell and interior nuclear layer to the imply reflectivity of RPE.
Outcomes: After Bonferroni correction, thinning in pericentral, superior and nasal sectors in whole retina, superior ganglion cell, pericentral and nasal interior plexiform, and superior interior retinal layers, in addition to thickening in inferior and pericentral outer plexiform layer remained vital within the examine group (p < 0.0125). Ganglion cell layer OIR considerably correlated with the modifications in superior retina (r = 0.278, p = 0.013), central interior retina (r = 0.247, p = 0.027), and pericentral retinal thickness (r = 0.240, p = 0.032), and no eyes had disruption of retinal layers within the examine group initially or lastly.
Conclusion: Ganglion cell layer reflectivity considerably correlated with the quantity of pericentral retinal thinning through the time course within the diabetic group, which was extra outstanding within the interior retinal layers.
RRAD Antibody |
|||
1-CSB-PA779820 | Cusabio |
|
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200 |
RRAD antibody |
|||
70R-50359 | Fitzgerald | 100 ul | EUR 292.8 |
Description: Purified Polyclonal RRAD antibody |
RRAD antibody |
|||
70R-5797 | Fitzgerald | 50 ug | EUR 560.4 |
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD |
RRAD antibody |
|||
70R-5798 | Fitzgerald | 50 ug | EUR 560.4 |
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD |
RRAD Antibody |
|||
37229-100ul | SAB | 100ul | EUR 302.4 |
RRAD Antibody |
|||
R34275-100UG | NSJ Bioreagents | 100 ug | EUR 399 |
RRAD Antibody |
|||
CSB-PA233809- | Cusabio | each | EUR 402 |
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500 |
Anti-RRAD (aa36-48) antibody |
|||
STJ72757 | St John's Laboratory | 100 µg | EUR 430.8 |
Rrad/ Rat Rrad ELISA Kit |
|||
ELI-14921r | Lifescience Market | 96 Tests | EUR 1063.2 |
RRAD Conjugated Antibody |
|||
C37229 | SAB | 100ul | EUR 476.4 |
Polyclonal RRAD Antibody |
|||
APR05556G | Leading Biology | 0.1ml | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human RRAD . This antibody is tested and proven to work in the following applications: |
RRAD siRNA |
|||
20-abx932133 | Abbexa |
|
|
RRAD Peptide |
|||
43-008P | ProSci | 0.1 mg | EUR 405.6 |
Description: RRAD Peptide |
RRAD Blocking Peptide |
|||
33R-4793 | Fitzgerald | 100 ug | EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5797 |
RRAD Blocking Peptide |
|||
33R-10070 | Fitzgerald | 100 ug | EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5798 |
RRAD Blocking Peptide |
|||
20-abx063234 | Abbexa |
|
|
Polyclonal Goat anti-GST α-form |
|||
GST-ANTI-1 | Detroit R&D | 50 uL | EUR 336 |
Polyclonal Goat anti-GST μ-form |
|||
GST-ANTI-2 | Detroit R&D | 50 uL | EUR 336 |
Polyclonal Goat anti-GST p-form |
|||
GST-ANTI-3 | Detroit R&D | 50 uL | EUR 336 |
Human RRAD shRNA Plasmid |
|||
20-abx954199 | Abbexa |
|
|
RRAD ELISA KIT|Human |
|||
EF005507 | Lifescience Market | 96 Tests | EUR 826.8 |
RRAD Recombinant Protein (Human) |
|||
RP095493 | ABM | 100 ug | Ask for price |
RRAD Recombinant Protein (Rat) |
|||
RP226925 | ABM | 100 ug | Ask for price |
RRAD Recombinant Protein (Mouse) |
|||
RP169340 | ABM | 100 ug | Ask for price |
GTP-Binding Protein RAD (RRAD) Antibody |
|||
20-abx008742 | Abbexa |
|
|
GTP-binding protein RAD (RRAD) Antibody |
|||
abx332370-100ul | Abbexa | 100 ul | EUR 510 |
GTP-Binding Protein RAD (RRAD) Antibody |
|||
abx432011-200ul | Abbexa | 200 ul | EUR 460.8 |
GTP-binding protein RAD (RRAD) Antibody |
|||
20-abx324872 | Abbexa |
|
|
GTP-binding protein RAD (RRAD) Antibody |
|||
20-abx241706 | Abbexa |
|
|
GTP-binding protein RAD (RRAD) Antibody |
|||
20-abx214509 | Abbexa |
|
|
Rrad ORF Vector (Rat) (pORF) |
|||
ORF075643 | ABM | 1.0 ug DNA | EUR 607.2 |
Rrad ORF Vector (Mouse) (pORF) |
|||
ORF056448 | ABM | 1.0 ug DNA | EUR 607.2 |
RRAD ORF Vector (Human) (pORF) |
|||
ORF031832 | ABM | 1.0 ug DNA | EUR 486 |
Polyclonal RRAD (aa36-48) Antibody (internal region) |
|||
APG00807G | Leading Biology | 0.1mg | EUR 580.8 |
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human RRAD (aa36-48) (internal region). This antibody is tested and proven to work in the following applications: |
RRAD And GEM Like GTPase 2 (REM2) Antibody |
|||
abx122938-100ug | Abbexa | 100 ug | EUR 469.2 |
RRAD And GEM Like GTPase 2 (REM2) Antibody |
|||
abx237237-100ug | Abbexa | 100 ug | EUR 661.2 |
Rrad sgRNA CRISPR Lentivector set (Rat) |
|||
K7052701 | ABM | 3 x 1.0 ug | EUR 406.8 |
Rrad sgRNA CRISPR Lentivector set (Mouse) |
|||
K3480701 | ABM | 3 x 1.0 ug | EUR 406.8 |
RRAD sgRNA CRISPR Lentivector set (Human) |
|||
K2069901 | ABM | 3 x 1.0 ug | EUR 406.8 |
Rrad sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
K7052702 | ABM | 1.0 ug DNA | EUR 184.8 |
Rrad sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
K7052703 | ABM | 1.0 ug DNA | EUR 184.8 |
Rrad sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
K7052704 | ABM | 1.0 ug DNA | EUR 184.8 |
Rrad sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
K3480702 | ABM | 1.0 ug DNA | EUR 184.8 |
Rrad sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
K3480703 | ABM | 1.0 ug DNA | EUR 184.8 |
Rrad sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
K3480704 | ABM | 1.0 ug DNA | EUR 184.8 |
RRAD sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
K2069902 | ABM | 1.0 ug DNA | EUR 184.8 |
RRAD sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
K2069903 | ABM | 1.0 ug DNA | EUR 184.8 |
RRAD sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
K2069904 | ABM | 1.0 ug DNA | EUR 184.8 |
RRAD Protein Vector (Human) (pPB-C-His) |
|||
PV127326 | ABM | 500 ng | EUR 662.4 |
RRAD Protein Vector (Human) (pPB-N-His) |
|||
PV127327 | ABM | 500 ng | EUR 662.4 |
RRAD Protein Vector (Human) (pPM-C-HA) |
|||
PV127328 | ABM | 500 ng | EUR 662.4 |
RRAD Protein Vector (Human) (pPM-C-His) |
|||
PV127329 | ABM | 500 ng | EUR 662.4 |
RRAD Protein Vector (Rat) (pPB-C-His) |
|||
PV302570 | ABM | 500 ng | EUR 723.6 |
RRAD Protein Vector (Rat) (pPB-N-His) |
|||
PV302571 | ABM | 500 ng | EUR 723.6 |
RRAD Protein Vector (Rat) (pPM-C-HA) |
|||
PV302572 | ABM | 500 ng | EUR 723.6 |
RRAD Protein Vector (Rat) (pPM-C-His) |
|||
PV302573 | ABM | 500 ng | EUR 723.6 |
RRAD Protein Vector (Mouse) (pPB-C-His) |
|||
PV225790 | ABM | 500 ng | EUR 723.6 |
RRAD Protein Vector (Mouse) (pPB-N-His) |
|||
PV225791 | ABM | 500 ng | EUR 723.6 |
RRAD Protein Vector (Mouse) (pPM-C-HA) |
|||
PV225792 | ABM | 500 ng | EUR 723.6 |
RRAD Protein Vector (Mouse) (pPM-C-His) |
|||
PV225793 | ABM | 500 ng | EUR 723.6 |
Rrad 3'UTR Luciferase Stable Cell Line |
|||
TU219725 | ABM | 1.0 ml | Ask for price |
Rrad 3'UTR GFP Stable Cell Line |
|||
TU168183 | ABM | 1.0 ml | Ask for price |
Rrad 3'UTR GFP Stable Cell Line |
|||
TU269725 | ABM | 1.0 ml | Ask for price |
Rrad 3'UTR Luciferase Stable Cell Line |
|||
TU118183 | ABM | 1.0 ml | Ask for price |
RRAD 3'UTR GFP Stable Cell Line |
|||
TU072380 | ABM | 1.0 ml | EUR 1672.8 |
RRAD 3'UTR Luciferase Stable Cell Line |
|||
TU022380 | ABM | 1.0 ml | EUR 1672.8 |
Human GTP-binding protein RAD (RRAD) ELISA Kit |
|||
abx385354-96tests | Abbexa | 96 tests | EUR 1093.2 |
Rat GTP-binding protein RAD (RRAD) ELISA Kit |
|||
abx391893-96tests | Abbexa | 96 tests | EUR 1093.2 |
Mouse GTP-binding protein RAD (RRAD) ELISA Kit |
|||
abx390415-96tests | Abbexa | 96 tests | EUR 1093.2 |
RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
LV658369 | ABM | 1.0 ug DNA | EUR 616.8 |
RRAD Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
LV658373 | ABM | 1.0 ug DNA | EUR 616.8 |
RRAD Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
LV658374 | ABM | 1.0 ug DNA | EUR 616.8 |
Human GTP- binding protein RAD, RRAD ELISA KIT |
|||
ELI-35549h | Lifescience Market | 96 Tests | EUR 988.8 |
Mouse GTP- binding protein RAD, Rrad ELISA KIT |
|||
ELI-14089m | Lifescience Market | 96 Tests | EUR 1038 |
Human RRAD And GEM Like GTPase 2 (REM2) ELISA Kit |
|||
abx382769-96tests | Abbexa | 96 tests | EUR 1093.2 |
Rrad ELISA Kit| Mouse GTP-binding protein RAD ELISA Kit |
|||
EF016057 | Lifescience Market | 96 Tests | EUR 826.8 |
Rrad ELISA Kit| Rat GTP-binding protein RAD ELISA Kit |
|||
EF019253 | Lifescience Market | 96 Tests | EUR 826.8 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
K7052705 | ABM | 3 x 1.0 ug | EUR 451.2 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
K3480705 | ABM | 3 x 1.0 ug | EUR 451.2 |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
K2069905 | ABM | 3 x 1.0 ug | EUR 451.2 |
RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
LV658370 | ABM | 1.0 ug DNA | EUR 616.8 |
RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
LV658371 | ABM | 1.0 ug DNA | EUR 686.4 |
RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
LV658372 | ABM | 1.0 ug DNA | EUR 686.4 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
K7052706 | ABM | 1.0 ug DNA | EUR 200.4 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
K7052707 | ABM | 1.0 ug DNA | EUR 200.4 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
K7052708 | ABM | 1.0 ug DNA | EUR 200.4 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|||
K3480706 | ABM | 1.0 ug DNA | EUR 200.4 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|||
K3480707 | ABM | 1.0 ug DNA | EUR 200.4 |
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|||
K3480708 | ABM | 1.0 ug DNA | EUR 200.4 |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
K2069906 | ABM | 1.0 ug DNA | EUR 200.4 |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
K2069907 | ABM | 1.0 ug DNA | EUR 200.4 |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
K2069908 | ABM | 1.0 ug DNA | EUR 200.4 |
Positive control tissue section for each individua |
|||
Control-Slides-for-each-antibody | Innovex | Set of 25 | EUR 355 |
Description: Positive control tissue section for each individual antibody; Based on availability; INQUIRE |
Anti-Anti-SEPT6 antibody antibody |
|||
STJ11100949 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined. |
Anti-Anti-SEPT9 Antibody antibody |
|||
STJ111369 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described. |
Anti-Anti-SEPT11 Antibody antibody |
|||
STJ111530 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT4 Antibody antibody |
|||
STJ112276 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer. |
Anti-Anti-MARCH9 Antibody antibody |
|||
STJ112609 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT2 Antibody antibody |
|||
STJ25475 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT5 Antibody antibody |
|||
STJ25477 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
Anti-Anti-SEPT8 Antibody antibody |
|||
STJ25479 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-SEPT2 Antibody antibody |
|||
STJ28365 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT7 Antibody antibody |
|||
STJ28963 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
Anti-Anti-SEPT1 antibody antibody |
|||
STJ119580 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012] |
Anti-Anti-SEPT12 Antibody antibody |
|||
STJ117759 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-MARCH6 Antibody antibody |
|||
STJ118549 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-MARCH6 Antibody antibody |
|||
STJ118550 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-MARCH7 Antibody antibody |
|||
STJ118752 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT3 Antibody antibody |
|||
STJ118990 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT11 Antibody antibody |
|||
STJ113941 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT11 Antibody antibody |
|||
STJ114081 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT5 Antibody antibody |
|||
STJ114819 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
Anti-Anti-MARCH8 Antibody antibody |
|||
STJ114828 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT7 Antibody antibody |
|||
STJ116214 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
Anti-Anti-SEPT8 Antibody antibody |
|||
STJ117206 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-DDB1 Antibody |
|||
A00333 | BosterBio | 100uL | EUR 546 |
Description: Rabbit Polyclonal DDB1 Antibody. Validated in IP and tested in Human, Mouse. |
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
|||
AEA465Hu-10x96wellstestplate | Cloud-Clone | 10x96-wells test plate | EUR 6777.36 |
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids. |
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
|||
AEA465Hu-1x48wellstestplate | Cloud-Clone | 1x48-wells test plate | EUR 663.31 |
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids. |
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
|||
AEA465Hu-1x96wellstestplate | Cloud-Clone | 1x96-wells test plate | EUR 896.16 |
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids. |
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
|||
AEA465Hu-5x96wellstestplate | Cloud-Clone | 5x96-wells test plate | EUR 3672.72 |
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids. |
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
|||
4-AEA465Hu | Cloud-Clone |
|
|
Description: Enzyme-linked immunosorbent assay based on the Competitive Inhibition method for detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in samples from serum, plasma and other biological fluids with no significant corss-reactivity with analogues from other species. |
ELISA kit for Human Anti-AsAb (Anti-Anti-Sperm Antibody Antibody) |
|||
ELK8071 | ELK Biotech | 1 plate of 96 wells | EUR 518.4 |
Description: A competitive Inhibition ELISA kit for detection of Anti-Anti-Sperm Antibody Antibody from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids. |
Anti-H4K20me1 Antibody |
|||
CI1005 | BosterBio | 100ul | EUR 589.2 |
Description: Rabbit Polyclonal H4K20me1 Antibody. Validated in ChIP, ChIP-qPCR, WB and tested in Human. |
Anti-H4K20me3 Antibody |
|||
CI1011 | BosterBio | 100ul | EUR 589.2 |
Description: Rabbit Polyclonal H4K20me3 Antibody. Validated in ChIP, ChIP-qPCR, WB and tested in Human. |
Anti-TIP5 Antibody |
|||
CI1016 | BosterBio | 100ul | EUR 589.2 |
Description: Rabbit Polyclonal TIP5 Antibody. Validated in ChIP, ChIP-qPCR, WB and tested in Human, Mouse. |
Anti-H4K8ac Antibody |
|||
CI1021 | BosterBio | 100ul | EUR 589.2 |
Description: Rabbit Polyclonal H4K8ac Antibody. Validated in ChIP, ChIP-qPCR, WB and tested in Human. |
Anti-MYH11 Antibody |
|||
CI1028 | BosterBio | 100ul | EUR 589.2 |
Description: Rabbit Polyclonal MYH11 Antibody. Validated in ChIP, ChIP-qPCR, ChIP-seq, IHC, WB and tested in Human. |
Anti-Ski3 Antibody |
|||
CI1031 | BosterBio | 150ug/50ul | EUR 589.2 |
Description: Rabbit Polyclonal Ski3 Antibody. Validated in ChIP, ChIP-qPCR, IF, IHC, WB and tested in Human. |
Anti-Ski8 Antibody |
|||
CI1032 | BosterBio | 150ug/60ul | EUR 589.2 |
Description: Rabbit Polyclonal Ski8 Antibody. Validated in ChIP, ChIP-qPCR, WB and tested in Drosophila, Human. |
Anti-H4K5,8,12ac Antibody |
|||
CI1033 | BosterBio | 50ug/66ul | EUR 589.2 |
Description: Rabbit Polyclonal H4K5,8,12ac Antibody. Validated in ChIP, ChIP-qPCR, ChIP-seq, IF, IHC, WB and tested in Human, Mouse. |
Anti-H4K5,8,12,16ac Antibody |
|||
CI1035 | BosterBio | 50ug/66ul | EUR 589.2 |
Description: Rabbit Polyclonal H4K5,8,12,16ac Antibody. Validated in ChIP, ChIP-qPCR, ChIP-seq, IF, IHC, WB and tested in Human, Mouse. |
Anti-H4K5ac Antibody |
|||
CI1036 | BosterBio | 50ug/28ul | EUR 589.2 |
Description: Rabbit Polyclonal H4K5ac Antibody. Validated in ChIP, ChIP-qPCR, ChIP-seq, IHC, WB and tested in Human, Mouse. |